Dogwood Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Dogwood Therapeutics, Inc. (formerly known as Virios Therapeutics, Inc. until its name change in October 2024) is a clinical-stage, pre-revenue biotechnology company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The company's research pipeline is anchored by two primary development candidates: Halneuron® and SP16 IV. Halneuron® is a highly selective voltage-gated sodium channel blocker targeting NaV 1.7, currently in Phase 2b development for moderate-to-severe chemotherapy-induced neuropathic pain (CINP) and cancer-related pain. SP16 IV is a low-density lipoprotein receptor-related protein-1 (LRP1) agonist designed to treat neuropathy and prevent or repair nerve damage following chemotherapy. Additionally, the company's pipeline includes combination antiviral therapies (IMC-1 and IMC-2) targeting viral-triggered abnormal immune responses associated with fibromyalgia and Long-COVID.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead candidate Halneuron® (a highly selective sodium channel blocker) through its Phase 2b clinical trial for chemotherapy-induced neuropathic pain, which has enrolled 164 patients.
Expected impact: Validation of efficacy and safety to support Phase 3 clinical trial design and regulatory submissions.
Advancing SP16 IV, a novel first-in-class candidate for chemotherapy-induced pain and peripheral neuropathy, into clinical trials following FDA acceptance of its Investigational New Drug (IND) application.
Expected impact: Expansion of the clinical-stage pipeline with non-dilutive funding.
Developing a chemically synthesized version of Halneuron® to replace the biological extract formulation, aimed at reducing manufacturing costs and improving yields for Phase 3 development.
Expected impact: Lower cost of goods sold (COGS), improved manufacturing scalability, and extended patent protection up to 2046.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Out-licenses legacy combination antiviral assets (IMC-1 and IMC-2) to allow Dogwood to focus resources entirely on its core pain and neuropathy pipeline.
Terms: PRIDCor is fully responsible for financing and executing future development, commercialization, and IP maintenance. Dogwood and its CVR holders are eligible for potential upfront and milestone payments of up to $100 million, plus tiered royalties on net sales.